| Literature DB >> 34554366 |
Martina Benker1, Necati Citak1, Thomas Neuer1, Isabelle Opitz1, Ilhan Inci2.
Abstract
OBJECTIVE: This study aimed to analyze whether comorbidities impact postoperative complication rate or survival after anatomical lung resection for non-small cell lung cancer (NSCLC).Entities:
Keywords: Comorbidity; Complication; Lung resection; NSCLC
Mesh:
Year: 2021 PMID: 34554366 PMCID: PMC8881261 DOI: 10.1007/s11748-021-01710-5
Source DB: PubMed Journal: Gen Thorac Cardiovasc Surg ISSN: 1863-6705
Postoperative complications
| Type of complication | Frequency |
|---|---|
| Pulmonary | |
| Pneumonia | 70 (5.7%) |
| Prolonged air leak | 65 (5.3%) |
| Pneumothorax | 56 (4.6%) |
| Hematothorax | 20 (1.6%) |
| Empyema | 22 (1.6%) |
| Acute respiratory distress syndrome | 17 (1.4%) |
| Pleural effusion | 13 (1.1%) |
| Bronchopleural fistula | 11 (0.9%) |
| Atelectasis | 11 (0.9%) |
| Chylothorax | 9 (0.7%) |
| Cardiac | |
| Arrhythmia | 149 (12.2%) |
| Hypertension | 29 (2.4%) |
| Myocardial infarction | 3 (0.2%) |
| Gastrointestinal | |
| Ileus | 9 (0.7%) |
| Others (Colitis, Ulcer, Bleeding, Ischemia) | 27 (2.2%) |
| Local/Systemic | |
| Wound infection | 26 (2.1%) |
| Paralysis of recurrent laryngeal nerve | 26 (2.1%) |
| Sepsis | 19 (1.6%) |
| Seroma | 18 (1.5%) |
| Renal insufficiency | 13 (1.1%) |
| Delirium | 9 (0.7%) |
| Aerodermectasia | 8 (0.7%) |
Patient demographic, tumor, and surgery characteristics of all patients, patients without complications, and patients with complications
| Variable category | All patients | Complications | ||
|---|---|---|---|---|
| None | One or more | |||
| Age | 64.24 (9.53) | 63.01 (9.41) | 66.20 (9.40) | < 0.001 |
| Gender | 0.102 | |||
| Female | 458 (37.6%) | 295 (24.2%) | 163 (13.4%) | |
| Male | 761 (62.4%) | 924 (75.8%) | 1056 (86.6%) | |
| Mean body mass index | 25.14 (4.65) | 25.32 (4.71) | 24.86 (4.54) | 0.094 |
| Body mass index category | 0.374 | |||
| Underweight | 64 (5.3%) | 34 (4.5%) | 30 (6.4%) | |
| Normal | 639 (52.4%) | 387 (51.7%) | 252 (53.5%) | |
| Overweight | 373 (30.6%) | 234 (31.3%) | 139 (29.5%) | |
| Obese | 143 (11.7%) | 93 (12.4%) | 50 (10.6%) | |
| FEV1% predicted | 84.17 (20.98) | 85.64 (20.73) | 81.84 (21.17) | 0.002 |
| Forced vital capacity | 95.05 (18.92) | 96.42 (18.79) | 92.88 (18.95) | 0.001 |
| Packyears | 41.90 (31.05) | 40.79 (30.95) | 43.66 (31.17) | 0.116 |
| Tumor stage | 0.135 | |||
| I | 428 (35.1%) | 274 (36.6%) | 154 (32.7%) | |
| II | 293 (24.0%) | 162 (21.7%) | 131 (27.8%) | |
| III | 399 (32.8%) | 246 (32.9%) | 153 (32.5%) | |
| IV | 99 (8.1%) | 66 (8.8%) | 33 (7.0%) | |
| Histology diagnosis | 0.214 | |||
| Adenocarcinoma | 613 (50.3%) | 390 (52.1%) | 223 (47.3%) | |
| Squamous cell carcinoma | 382 (31.3%) | 225 (30.5%) | 157 (33.3%) | |
| Carcinoid | 80 (6.6%) | 53 (7.1%) | 27 (5.7%) | |
| Large cell carcinoma | 60 (4.9%) | 31 (4.1%) | 29 (6.2%) | |
| Other | 84 (6.9%) | 49 (6.6%) | 35 (7.4%) | |
| Neoadjuvant treatment | 0.235 | |||
| None | 1005 (82.4%) | 609 (81.4%) | 396 (84.1%) | |
| Chemotherapy | 176 (14.4%) | 111 (14.8%) | 65 (13.8%) | |
| Radiotherapy and chemotherapy | 38 (3.1%) | 28 (3.7%) | 10 (2.1%) | |
| Surgery | 0.076 | |||
| Open | 839 (68.8%) | 508 (67.9%) | 331 (70.3%) | |
| Minimally invasive | 179 (14.7%) | 123 (16.4%) | 56 (11.9%) | |
| Conversion | 201 (16.5%) | 117 (15.6%) | 84 (17.8%) | |
| Surgery type | 0.437 | |||
| Lobectomy | 819 (67.2%) | 509 (68.0%) | 310 (65.8%) | |
| Sleeve resection | 181 (14.8%) | 113 (15.1%) | 68 (14.4%) | |
| Pneumonectomy | 219 (18.0%) | 126 (16.8%) | 93 (19.7%) | |
Data are in the form of mean (standard deviation) or frequency (percentage)
Associations of comorbidities, by type and by specific diagnosis, with the occurrence of complications in patients following anatomical Non-small cell lung cancer tumor resection
| Type of comorbidity | Overall | Complications | ||
|---|---|---|---|---|
| None | One or more | |||
| Pulmonary | ||||
| Diagnosis of chronic obstructive pulmonary disease (any stage) | 322 (26.4%) | 191 (25.5%) | 131 (27.8%) | 0.417 |
| Chronic obstructive pulmonary disease GOLD stage | 0.61 | |||
| I | 91 (7.5%) | 58 (7.8%) | 33 (7.0%) | |
| II | 181 (14.8%) | 104 (13.9%) | 77 (16.3%) | |
| III | 50 (4.1%) | 29 (3.9%) | 21 (4.5%) | |
| Cardiovascular | ||||
| Arterial hypertension | 416 (34.1%) | 243 (32.5%) | 173 (36.7%) | 0.144 |
| Coronary heart disease | 155 (12.7%) | 83 (11.1%) | 72 (15.3%) | 0.04 |
| Peripheral artery disease | 104 (8.5%) | 57 (7.6%) | 47 (10.0%) | 0.184 |
| Myocardial infarction history | 35 (2.9%) | 22 (2.9%) | 13 (2.8%) | 0.993 |
| Other comorbidity | ||||
| Diabetes mellitus | 129 (10.6%) | 70 (9.4%) | 59 (12.5%) | 0.098 |
| Renal insufficiency | 90 (7.4%) | 47 (6.3%) | 43 (9.1%) | 0.082 |
| Other malignancy | 232 (19%) | 145 (19.4%) | 87 (18.5%) | 0.748 |
Fig. 1Forest plot depicting the impacts of patient characteristics and preoperative comorbidities on the overall occurrence of postoperative complications. A more advanced age, lower BMI, and lower FEV1 were significantly associated with a greater complication rate
Fig. 2Cox proportional-hazard analysis showing independent influencing factors on survival. Significant factors are indicated with *p < 0.05, **p < 0.01, and ***p < 0.001